Loading...
XJPX
9987
Market cap2.22bUSD
Oct 09, Last price  
2,600.00JPY
1D
0.37%
1Q
5.31%
Jan 2017
36.13%
Name

Suzuken Co Ltd

Chart & performance

D1W1MN
XJPX:9987 chart
P/E
9.22
P/S
0.14
EPS
281.91
Div yield, %
3.86%
Shrs. gr., 5y
9.41%
Rev. gr., 5y
3.16%
Revenues
2.49t
+3.61%
1,454,841,000,0001,586,596,000,0001,641,331,000,0001,735,476,000,0001,751,928,000,0001,859,917,000,0001,894,611,000,0001,988,137,000,0001,969,683,000,0002,228,204,000,0002,127,076,000,0002,124,016,000,0002,132,345,000,0002,213,532,000,0002,128,478,000,0002,239,112,000,0002,314,828,000,0002,386,493,000,0002,399,952,000,0002,486,647,000,000
Net income
38.14b
+10.55%
17,701,000,00021,327,000,0007,072,000,00013,969,000,0009,627,000,0008,050,000,00014,350,000,00021,447,000,00018,920,000,00028,960,000,00021,309,000,00018,821,000,00030,205,000,00028,213,000,0007,896,000,00014,394,000,00020,345,000,00029,016,000,00034,497,000,00038,136,000,000
CFO
33.57b
P
68,115,000,000-16,118,000,000-4,585,000,00031,913,000,00028,336,000,00065,542,000,00054,006,000,000-41,054,000,00047,209,000,00020,457,000,00027,013,000,00098,066,000,00041,751,000,000-25,817,000,00015,602,000,0009,520,000,00037,270,000,00087,216,000,000-65,079,000,00033,566,000,000
Dividend
Mar 30, 202730 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Suzuken Co., Ltd., along with its affiliated companies, operates primarily as a global wholesaler of pharmaceutical products, with a strong presence both in Japan and internationally. The company's diverse activities are structured into four main divisions: Pharmaceutical Distribution, Pharmaceutical Manufacturing, Pharmacy Services, and Healthcare-Related Services. The Pharmaceutical Distribution segment focuses on sourcing a wide array of items, including prescription medications, diagnostic substances, various medical devices and supplies, and other health-focused goods directly from manufacturers. These products are then supplied to medical facilities and pharmacies. In its Pharmaceutical Manufacturing division, Suzuken engages in the research, development, production, and marketing of ethical pharmaceuticals and diagnostic tools, with a particular emphasis on treatments for diabetes and kidney diseases. Through its Pharmacy Services segment, the company provides support via community pharmacists, while also striving to optimize the operations of local pharmacies and offering essential educational assistance. Finally, the Healthcare-Related Services division offers a broad spectrum of functions. This includes providing support for manufacturers, such as outsourced distribution and the specialized distribution of orphan drugs, in addition to delivering nursing care services. This segment is also responsible for the design, manufacturing, and sale of medical instruments like ECG machines, blood pressure monitors, and stethoscopes, as well as general medical materials and equipment for health promotion. Beyond these core business areas, Suzuken Co., Ltd. also publishes medical periodicals specifically for healthcare professionals and institutions. The company has also forged a strategic alliance with Bushu Pharmaceuticals Ltd. to offer specialized contract drug services. Suzuken Co., Ltd. was established in 1932 and is headquartered in Nagoya, Japan.

Key people

Hiromi Miyata
Chairman of the Executive Board, Director · since 2024
Shigeru Asano
Executive President, Chief Executive Officer, Representative Director · since 2022
Yuichiro Daikoku
Managing Executive Officer, Chief Director of Digital Solutions Manager · since 2025
Akihiko Someya
Managing Executive Officer, Director of Nagoya Sales · since 2023
Osamu Abe
Senior Executive Officer, Director of Osaka Sales · since 2021
Naoaki Kato
Senior Executive Officer, Director of Tokyo Central Sales · since 2021
Yoshihiro Ohtsuka
Senior Executive Officer, Senior Director of Insurance Pharmacy · since 2024
Chie Takahashi
Senior Executive Officer, Chief Director of Medical and Nursing Support Business, Director of Business Planning, Director · since 2023
Yasuyoshi Fujii
Executive Officer, Director of Aiseikan Sales · since 2024
Koichiro Nakamura
Executive Officer, Director of Yokohama Sales · since 2023
Takashi Saito
Executive Officer, Director of Saitama Sales · since 2024
Hideo Takagi
Executive Officer, Director of Tokyo Hospital Sales · since 2023
Seita Ando
Executive Officer, Deputy Chief Director of Digital Solution Management · since 2025
Takeru Hiki
Executive Officer, Chief Director of Digital Platform Business · since 2024
Kouji Momobayashi
Executive Officer, Senior Director of Hospital · since 2023
Kenji Nameda
Executive Officer, Deputy Chief Director of Main Medical and Nursing Support Unit, Director of Medical and Nursing Support Business · since 2024
Koji Sakashita
Executive Officer, Deputy Chief Director of Main Digital Platform Business Unit · since 2024
Yuichi Yamamoto
Executive Officer, Chief Director of Group Planning, Director of Business Planning · since 2023
Hisashi Tamura
Director · since 2023
Hirofumi Tanaka
Senior Managing Executive Officer, Chief Director of Healthcare Distribution Business, Director · since 2023
IPO date
Aug 01, 1994
Employees
13,429
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT